Dynogen utilizes its expertise in the connection between neurology and GU/GI disorders, along with its predictive pharmacology platforms, to quickly develop a pipeline of programs. Currently, the company has two ongoing programs for overactive bladder and irritable bowel syndrome. The OAB program will enter Phase IIa trials, while the IBS program will enter the clinic later this year.